In COGA AA families, individuals with elevated fast beta EEG were more likely to meet criteria for AD (P<0.01), and a small, but significant portion of the variance shared among fast beta EEG and AD is attributable to genome-wide variants (genetic correlation, as estimated by GCTA: 0.10, s.e.: 0.17). There is evidence of association between 4 of the 10 variants meeting genome-wide criteria for fast beta EEG and AD (rs7428372 and rs13093097 survived a multiple test correction), suggesting a potential protective role for fast beta EEG variants in AD in the primary GWAS sample. Further, 4 of the 10 SNPs meeting genome-wide criteria for fast beta EEG in COGA were nominally associated with AD in an independent sample,46 and 2 of these SNPs withstood multiple test correction. Interestingly, these two variants, rs7428372 and rs13093097 (r2>0.97), were two of the four variants that withstood a multiple test correction in the discovery sample.
